论文部分内容阅读
对127例原发性肝癌患者及96例肝血管瘤患者测定了血清甘氨酰脯氨酸二肽氨基肽酶(GPDA),并以86名健康献血员作为对照。结果表明:原发性肝癌患者的GPDA阳性率为67.7％,而血管瘤患者和健康献血员中均未出现阳性,原发性肝癌与肝血管瘤之间有极显著性差异(P<0.001)。肝血管瘤与正常人之间差异无显著性(P>0.05)。结果还显示AFP阴性肝癌患者的GPDA阳性率达70％,GPDA与AFP无相关性。结果表明血清GPDA测定有助于肝癌与肝血管瘤之间的鉴别诊断。文章对GPDA作为肝癌标志物的诊断价值作了讨论。
The serum glycylproline dipeptide aminopeptidase (GPDA) was measured in 127 patients with primary liver cancer and 96 patients with hepatic hemangiomas, and 86 healthy blood donors were used as controls. The results showed that the positive rate of GPDA in patients with primary liver cancer was 67.7%, but none of the patients with hemangiomas and healthy blood donors were positive, and there was a significant difference between primary liver cancer and hepatic hemangioma (P<0.001). . There was no significant difference between hemangiomas and normal people (P>0.05). The results also showed that the positive rate of GPDA in patients with AFP-negative liver cancer was 70%, and there was no correlation between GPDA and AFP. The results show that serum GPDA assay is helpful for the differential diagnosis between hepatocellular carcinoma and hepatic hemangiomas. The article discusses the diagnostic value of GPDA as a marker of liver cancer.